Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00121511
Other study ID # Derm 549
Secondary ID 2005-0368
Status Completed
Phase N/A
First received July 13, 2005
Last updated May 26, 2015
Start date July 2005
Est. completion date July 2007

Study information

Verified date May 2015
Source University of Michigan
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The researchers propose that skin improvements may be seen following a course of Efudex, (5-fluorouracil), a FDA-approved topical therapy (applied directly to the skin). These improvements could be the result of both a reduction of actinic keratoses (small red horny growths or flesh-colored wartlike growths caused by overexposure to ultraviolet radiation or the sun) and improvement of sun-damaged skin.

In addition, this research study is being done to determine if the expression of p53, a tumor suppressor gene (its activity stops the formation of tumors), is decreased following Efudex treatment. Mutations (abnormal changes) in the gene, called p53, are associated with a certain type of skin cancer. In addition, p53-mutated genes are known to exist in non-cancerous sun-damaged skin. Thus, the presence of p53 mutations may serve as a marker for both sun damage and an elevated risk of developing skin cancer.


Description:

Efudex (5-fluorouracil) has been used as topical chemotherapy for the treatment of actinic keratoses (AKs) since the 1950's. Through many years of use, Efudex has been deemed to be a safe and effective therapy. It requires, however, a high level of patient compliance and is known to cause a vigorous inflammatory reaction when actinic keratoses are treated. It has the distinct advantage of identifying precancerous skin lesions not apparent on clinical inspection or palpation. Following a course of Efudex to the face, patients have been noted to have fewer signs of dermatoheliosis.

The investigators propose to determine if Efudex is associated with improvement of aging skin in the setting of treating actinic keratoses. The researchers hope to demonstrate less p53 staining following Efudex treatment. It is proposed that the skin improvements seen following a course of Efudex are due to both reduction of actinic keratoses and impact on photoaging. The researchers propose to quantify the effects of Efudex therapy on the immunohistochemical staining properties of facial skin with respect to p53 and procollagen. The hypothesis is that Efudex therapy will decrease p53 immunostaining thus providing biochemical evidence to support this treatment in the reduction of actinic keratoses with concomitant improvement of aging skin.


Recruitment information / eligibility

Status Completed
Enrollment 21
Est. completion date July 2007
Est. primary completion date
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 50 Years and older
Eligibility Inclusion Criteria:

- Age 50 or older of either gender.

- Patients must have actinic keratoses

- Patients must have clinical photoaging judged by rhytides, dyspigmentation, poikiloderma, lentigines, skin thinning, and/or telangiectases.

- Subjects must be in generally good health and willing to undergo skin biopsies from the face.

- Subjects must be willing and able to comply with the requirements of the protocol.

- You must live within a reasonable driving distance of Ann Arbor, Michigan, and/or be able to attend all of the scheduled appointments during the study.

Exclusion Criteria:

- Oral retinoid therapy (such as Accutane) within two months of study entry.

- Topical retinoid, imiquimod, or diclofenac therapy within 2 months of study entry.

- Prior laser re-surfacing, chemical peels for actinic keratoses or aging skin.

- Pregnant or nursing subjects.

- Non-compliant subjects.

- Subjects with a significant medical history or concurrent illness that the investigator feels is not safe for study participation.

- Prior systemic treatment with 5-fluorouracil.

- Known history of allergy to lidocaine (numbing medication), 5-fluoruracil, or any other known components of Efudex.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Efudex (5-fluorouracil)


Locations

Country Name City State
United States University of Michigan Department of Dermatology Ann Arbor Michigan

Sponsors (2)

Lead Sponsor Collaborator
University of Michigan Valeant Pharmaceuticals International, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Actinic Keratoses resolution and improvement in photoaging
Secondary Changes in p53 immunostaining intensity will be used to assess response
Secondary Collagen production will be evaluated by Western blotting, immunohistology, and RT-PCR
See also
  Status Clinical Trial Phase
Completed NCT00239135 - Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel Phase 2
Recruiting NCT06206681 - Efficacy and Safety of Ultrapulse Carbon Dioxide Laser Treatment in Eyelid Tumors
Completed NCT00115154 - Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Arms and Hands Phase 4
Recruiting NCT04336514 - A Longitudinal Quantitative Assessment of the Effectiveness of Metatarsal Pads on Plantar Pressures N/A
Completed NCT00116649 - Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis Phase 4
Recruiting NCT05942794 - Identification of Oral Lesions Through an Autofluorescence System N/A
Withdrawn NCT02851693 - Study of Imaging Characteristics OCT of Skin Lesions Requiring Biopsy / Resection N/A
Withdrawn NCT02813902 - A Trial of Polypodium Leucotomos in Preventing Skin Cancer and Its Precursors Phase 1
Completed NCT00114023 - 1-Year Follow up to the 1473-IMIQ Study Phase 3
Completed NCT05060237 - Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp Phase 1
Recruiting NCT02737176 - Tobacco Cessation Intervention Study for Oral Diseases N/A
Completed NCT00110682 - Study of Imiquimod 5% Cream in Addition to Cryotherapy in the Management of Actinic Keratoses Phase 4